Madrigal Pharmaceuticals ...

NASDAQ: MDGL · Real-Time Price · USD
270.47
-1.10 (-0.41%)
At close: May 28, 2025, 3:59 PM
270.70
0.09%
After-hours: May 28, 2025, 05:18 PM EDT

Company Description

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases.

Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis.

The company also develops MGL-3745, a backup compound to resmetirom.

It has research, development, and commercialization agreement with Hoffmann-La Roche.

Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc. logo
Country United States
IPO Date Feb 6, 2007
Industry Biotechnology
Sector Healthcare
Employees 528
CEO William J. Sibold

Contact Details

Address:
Four Tower Bridge
West Conshohocken, Pennsylvania
United States
Website https://www.madrigalpharma.com

Stock Details

Ticker Symbol MDGL
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001157601
CUSIP Number 558868105
ISIN Number US5588681057
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
William J. Sibold Chief Executive Officer, President & Director
Mardi C. Dier Executive Vice President & Chief Financial Officer
Ronald Filippo Executive Vice President & Chief Information Officer
Shannon Kelley Executive Vice President, Chief Legal Officer & Corporate Secretary
Carole Huntsman Executive Vice President & Chief Commercial Officer
Clint Wallace Executive Vice President & Chief Human Resources Officer
Dr. Rebecca A. Taub M.D. Founder, Senior Scientific & Medical Advisor and Director
Edward Chiang Senior Vice President of Clinical & Technical Operations
Mark Underwood Executive Vice President of Business Planning & Operations
Tina E. Ventura Chief Investor Relations Officer

Latest SEC Filings

Date Type Title
May 16, 2025 4 Filing
May 14, 2025 SCHEDULE 13G/A [Amend] Filing
May 01, 2025 10-Q Quarterly Report
May 01, 2025 8-K Current Report
Apr 29, 2025 ARS Filing
Apr 29, 2025 DEFA14A Filing
Apr 29, 2025 DEF 14A Filing
Apr 24, 2025 3 Filing
Apr 17, 2025 8-K Current Report
Mar 14, 2025 4 Filing